You are here

  • Home
  • Archive
  • Volume 13, Issue 1
  • Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

Article metrics

Article menu
Download PDFPDF
Letter
Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic

 

Online download statistics by month:

Online download statistics by month: May 2021 to March 2024

AbstractFullPdf
May 202110410433
Jun 20211049827
Jul 202141415
Aug 202151516
Sep 2021414116
Oct 2021384024
Nov 2021444431
Dec 202115015350
Jan 202217117354
Feb 2022656226
Mar 2022595540
Apr 2022484920
May 2022544940
Jun 2022646020
Jul 2022656116
Aug 2022676718
Sep 2022908929
Oct 2022756926
Nov 2022666317
Dec 2022756917
Jan 2023605818
Feb 202311511427
Mar 2023626515
Apr 20232391912
May 202319381
Jun 2023191911
Jul 202314453
Aug 202315199
Sep 20239221
Oct 202313696
Nov 20239692
Dec 202310223
Jan 20244623
Feb 202413636
Mar 20245633
Total32911755635